Read this topic

Valproate, carbamazepine, and lamotrigine are all anticonvulsants (drugs originally developed to treat epilepsy) that are also used as mood stabilisers in bipolar disorder. Exam questions group them precisely because they are easy to confuse: but each has its own distinct monitoring needs, its own safety profile, and its own drug interactions. Hold that word DISTINCT through every section below.

A mood stabiliser is a medication used to prevent or treat the extreme mood swings of bipolar disorder (a condition of alternating manic and depressive episodes). Valproate and carbamazepine are both established for acute mania; lamotrigine is used mainly for bipolar depression and relapse prevention, and is NOT considered effective for acute mania.

A common exam trap is treating all three as interchangeable 'anticonvulsant mood stabilisers'. They are not interchangeable in safety profile: valproate carries the highest reproductive risk, carbamazepine's biggest hazard is a drug-interaction one, and lamotrigine's biggest hazard is a skin reaction. Knowing WHICH danger belongs to WHICH drug is the actual exam skill.

Valproate inhibits GABA-transaminase, an enzyme that breaks down GABA (the brain's main inhibitory neurotransmitter), so GABA levels rise; it also blocks voltage-gated sodium channels. Carbamazepine is primarily a sodium-channel blocker. Lamotrigine also blocks sodium channels and additionally reduces the release of glutamate, an excitatory neurotransmitter. All three, by different routes, damp down excessive electrical activity in neurons: which is the shared property that makes them anticonvulsants in the first place.

Before starting valproate, baseline full blood count and liver function tests are checked, because valproate carries a risk of low platelets and liver toxicity. Other recognised side effects include tremor, weight gain, polycystic ovary syndrome, and hair loss. Its single most important safety issue is teratogenicity (the potential to cause birth defects): valproate is strongly linked to neural tube defects and developmental problems in a fetus. Because of this, the MHRA (Medicines and Healthcare products Regulatory Agency) runs a Pregnancy Prevention Programme requiring specific counselling, contraception, and annual risk-acknowledgement for anyone of childbearing potential prescribed valproate.

Carbamazepine's defining pharmacological feature is that it is a potent inducer of hepatic (liver) enzymes, particularly the cytochrome P450 system. This means it SPEEDS UP the breakdown of many other drugs: for example, a patient started on carbamazepine may find their oral contraceptive suddenly becomes less effective, because carbamazepine induces the enzymes that clear the contraceptive hormones faster than normal. The same induction effect lowers levels of clozapine and other anticonvulsants taken alongside it. Recognised side effects include double vision, unsteady movement (worse around peak drug levels), and low blood sodium (hyponatraemia).

Lamotrigine's defining safety issue is a skin rash, which in a small proportion of patients can progress to a severe, life-threatening reaction called Stevens-Johnson syndrome. The single most important protective measure is SLOW titration: starting at a low dose and increasing gradually over weeks, rather than raising the dose quickly. In practice, any rapid dose increase raises the risk of this severe reaction, which is why lamotrigine dosing schedules look deliberately cautious compared with other anticonvulsants.

Valproate and lamotrigine interact directly: valproate roughly DOUBLES lamotrigine blood levels, so when the two are combined the lamotrigine dose must be roughly halved. Carbamazepine has the opposite effect on lamotrigine: as an enzyme inducer, it roughly HALVES lamotrigine levels, so the lamotrigine dose typically needs to be higher when combined with carbamazepine. Any time one of these three drugs is added to, or removed from, a patient already taking lamotrigine, the lamotrigine dose needs active review.

These three are easy to lump together with lithium, the other classic mood stabiliser, but lithium is not an anticonvulsant at all: it works through a different mechanism, needs regular blood-level monitoring because of its narrow therapeutic index (a small window between an effective dose and a toxic one), and carries its own distinct risks, including hypothyroidism, nephrotoxicity (kidney damage) and cardiac malformation risk in the first trimester of pregnancy, rather than the neural tube defect risk specific to valproate. Within the anticonvulsant group itself, the same "distinct risk" logic from the caveat above applies: valproate, carbamazepine, and lamotrigine are all anticonvulsants, all used as mood stabilisers, and all reduce neuronal excitability: but confusing any one drug's headline risk for another's is the exact trap this page exists to prevent.

Diagnosis of bipolar disorder rests on defined criteria, not just a mood swing history in isolation. ICD-11 and DSM-5 both require at least one manic or hypomanic episode: a spell of clearly abnormal mood that is either persistently high, over-expansive, or irritable, together with a marked jump in energy or goal-directed activity, plus a set of accompanying features such as decreased need for sleep, grandiosity, pressured speech or risky behaviour. Depressive episodes are common in the illness but are not, on their own, sufficient for the diagnosis without a manic or hypomanic episode at some point. Before starting any of these three drugs, baseline assessment also has a physical component: for valproate, baseline full blood count and liver function tests; for carbamazepine, similarly baseline blood tests given its enzyme-inducing and blood-count effects; for lamotrigine, a clear plan for the slow titration schedule described above: the diagnosis alone does not tell you which drug or dose is safe to start immediately.

Management is guided by NICE's bipolar disorder guideline. First-line treatment for acute mania typically favours an antipsychotic, with valproate or another mood stabiliser considered alongside; lamotrigine's role is chiefly in preventing relapse into depression, not treating acute mania. Whenever valproate is considered in a person of childbearing potential, MHRA Pregnancy Prevention Programme counselling is mandatory before prescribing.

Questions often swap which drug has which risk, putting the rash with carbamazepine or the teratogenicity with lamotrigine, to test whether the distinction has actually been learned rather than just the group name. Anchor each drug to ONE headline risk: valproate to teratogenicity, carbamazepine to enzyme induction and drug interactions, lamotrigine to rash and the need for slow titration.

Anchor each drug to one headline risk (valproate to teratogenicity, carbamazepine to enzyme induction, lamotrigine to rash needing slow titration) and remember valproate roughly doubles, while carbamazepine roughly halves, co-prescribed lamotrigine levels.